Pharmacokinetic model for the enterohepatic circulation of mycophenolic acid

Yaoxue Xuebao

Volumn 41, Issue 3, 2006, Pages 272-276

  Jiao, Zheng ^a,b   Shen, Jie ^a,c   Zhong, Long Jin ^a   Yu, Yun Qiu ^b   Zhong, Ming Kang ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c HUADONG HOSPITAL AFFILIATED TO FUDAN UNIVERSITY   (China)

Author keywords

Enterohepatic circulation; Mycophenolic acid; Nonlinear mixed effect model

Indexed keywords

DRUG DERIVATIVE; GLUCURONIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; BLOOD; ENTEROHEPATIC CIRCULATION; HUMAN; MALE; PHYSIOLOGY;

ADULT; AREA UNDER CURVE; ENTEROHEPATIC CIRCULATION; GLUCURONIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID;

EID: 33646450903     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil [J]. Clin Pharmacokinet, 1998,34:429-455.
2. Shum B, Duffull SB, Taylor PJ, et al. Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil [J]. Br J Clin Pharmacol, 2003,56:188-197.
3. Le Guellec C, Bourgoin H, Buchler M, et al. Population pharmacokinetics and Bayesian estimation of mycophenolie acid concentrations in stable renal transplant patients [J]. Clin Pharmacokinet, 2004,43:253-266.
4. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? [J]. Ther Drug Monit, 2003,25:137-157.
5. Shen J, Jiao Z, Yu YQ, et al. Quantification of total and free mycophenolic acid in human plasma by liquid chromatography with fluorescence detection [J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2005,817:207-213.
6. Roberts MS, Magnusson BM, Burczynski FJ, et al. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications [J]. Clin Pharmacokinet, 2002,41:751-790.
7. Funaki T. Enterohepatic circulation model for population pharmacokinetic analysis [J]. J Pharm Pharmacol, 1999,51:1143-1148.
8. Sreenivasa V, Piotrovsky V, Rosenborg J, et al. Enterohepatic circulation [DB/OL]. [2002-06-11]. http://huxley.phor.com/nonmem/nm/98may312002. html.
9. Port RE. SOP 14: population pharmacokinetic analysis [J]. Onkologie, 2003,26:60-66.
10. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis [J]. AAPS PharmSci, 2002,4:E27.
11. Bhattaram VA, Gibiansky L, Hu C, et al. When to do transformation of data? [DB/OL]. [2002-04-29]. http://www.cognigencorp.com/nonmem/nm/99apr232002. html.
12. Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods [J]. Ann Pharmacother, 2004,38:1907-1915.